Neurogene (NGNE) Stock: Why It's Up Today
Updated Oct 19, 2026, 4:00 PM ET · closing price
- Closed at $24.17, +3.96% vs the prior close of $23.25.
- Volume 240.16K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
NGNE jumps 4.0% to $24.17. Closed at $24.17, +3.96% vs the prior close of $23.25. Day range $22.78–$24.39, opened at $23.26.
NGNE daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — NGNE jumps 4.0% to $24.17
- Closed at $24.17, +3.96% vs the prior close of $23.25. Day range $22.78–$24.39, opened at $23.26.
- Volume was 240.16K shares, 0.8x its 50-day average of 300.45K.
- Price is -25.9% vs its 50-day average ($32.62) and -12.0% vs its 200-day average ($27.46).
- 52-week range $15.93–$43.66; today's close sits at 30% of that range, 44.6% below the 52-week high.
Oct 16, 2026 — NGNE dips 2.9% to $23.25 on 2.0x normal volume
- Closed at $23.25, -2.92% vs the prior close of $23.95. Day range $23.00–$24.00, opened at $23.96.
- Volume was 571.50K shares, 2.0x its 50-day average of 290.90K — unusually heavy trading.
- Price is -29.2% vs its 50-day average ($32.85) and -15.3% vs its 200-day average ($27.45).
- 52-week range $15.93–$43.66; today's close sits at 26% of that range, 46.7% below the 52-week high.
Oct 15, 2026 — NGNE jumps 8.0% to $23.95 on 2.1x normal volume
- Closed at $23.95, +7.98% vs the prior close of $22.18. Day range $22.35–$24.41, opened at $22.35.
- Volume was 588.00K shares, 2.1x its 50-day average of 282.50K — unusually heavy trading.
- Price is -27.6% vs its 50-day average ($33.10) and -12.7% vs its 200-day average ($27.44).
- 52-week range $15.93–$43.66; today's close sits at 29% of that range, 45.1% below the 52-week high.
Oct 14, 2026 — NGNE rises 2.9% to $22.18 on 1.9x normal volume
- Closed at $22.18, +2.88% vs the prior close of $21.56. Day range $21.05–$22.50, opened at $21.05.
- Volume was 522.40K shares, 1.9x its 50-day average of 274.89K — unusually heavy trading.
- Price is -33.5% vs its 50-day average ($33.34) and -19.1% vs its 200-day average ($27.42).
- 52-week range $15.93–$43.66; today's close sits at 23% of that range, 49.2% below the 52-week high.
Oct 13, 2026 — NGNE slides 11.8% to $21.56, a 3-month low, 3 down days in a row
- Closed at $21.56, -11.78% vs the prior close of $24.44. Day range $21.40–$25.17, opened at $24.32.
- Volume was 441.40K shares, 1.6x its 50-day average of 269.17K.
- Price is -35.8% vs its 50-day average ($33.58) and -21.3% vs its 200-day average ($27.41).
- 52-week range $15.93–$43.66; today's close sits at 20% of that range, 50.6% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — NGNE slides 7.4% to $24.44, a 3-month low
- Closed at $24.44, -7.42% vs the prior close of $26.40. Day range $24.19–$27.15, opened at $26.13.
- Volume was 387.00K shares, 1.5x its 50-day average of 264.69K.
- Price is -27.7% vs its 50-day average ($33.81) and -10.8% vs its 200-day average ($27.40).
- 52-week range $15.93–$43.66; today's close sits at 31% of that range, 44.0% below the 52-week high.
Oct 9, 2026 — NGNE dips 0.4% to $26.40 on 1.8x normal volume
- Closed at $26.40, -0.38% vs the prior close of $26.50. Day range $26.01–$29.63, opened at $28.90.
- Volume was 465.90K shares, 1.8x its 50-day average of 257.24K — unusually heavy trading.
- Price is -22.3% vs its 50-day average ($33.98) and -3.6% vs its 200-day average ($27.38).
- 52-week range $15.93–$43.66; today's close sits at 38% of that range, 39.5% below the 52-week high.
Oct 8, 2026 — NGNE rises 2.4% to $26.50 on 2.0x normal volume
- Closed at $26.50, +2.44% vs the prior close of $25.87. Day range $26.24–$28.97, opened at $28.00.
- Volume was 509.40K shares, 2.0x its 50-day average of 249.69K — unusually heavy trading.
- Price is -22.3% vs its 50-day average ($34.12) and -3.1% vs its 200-day average ($27.35).
- 52-week range $15.93–$43.66; today's close sits at 38% of that range, 39.3% below the 52-week high.
Oct 7, 2026 — NGNE rises 1.7% to $25.87
- Closed at $25.87, +1.65% vs the prior close of $25.45. Day range $25.01–$26.00, opened at $25.14.
- Volume was 114.10K shares, 0.5x its 50-day average of 250.55K — lighter than usual.
- Price is -24.5% vs its 50-day average ($34.26) and -5.3% vs its 200-day average ($27.32).
- 52-week range $15.93–$43.66; today's close sits at 36% of that range, 40.7% below the 52-week high.
Oct 6, 2026 — NGNE slides 3.9% to $25.45, a 3-month low
- Closed at $25.45, -3.85% vs the prior close of $26.47. Day range $25.04–$26.74, opened at $26.63.
- Volume was 121.60K shares, 0.5x its 50-day average of 252.95K — lighter than usual.
- Price is -26.0% vs its 50-day average ($34.41) and -6.7% vs its 200-day average ($27.29).
- 52-week range $15.93–$43.66; today's close sits at 34% of that range, 41.7% below the 52-week high.
Oct 5, 2026 — NGNE jumps 3.2% to $26.47
- Closed at $26.47, +3.20% vs the prior close of $25.65. Day range $24.86–$26.76, opened at $25.71.
- Volume was 211.80K shares, 0.8x its 50-day average of 251.95K.
- Price is -23.5% vs its 50-day average ($34.59) and -2.9% vs its 200-day average ($27.26).
- 52-week range $15.93–$43.66; today's close sits at 38% of that range, 39.4% below the 52-week high.
Oct 2, 2026 — NGNE slides 3.4% to $25.65, a 3-month low, 4 down days in a row
- Closed at $25.65, -3.39% vs the prior close of $26.55. Day range $24.86–$26.95, opened at $26.95.
- Volume was 401.60K shares, 1.6x its 50-day average of 247.03K.
- Price is -26.2% vs its 50-day average ($34.76) and -5.8% vs its 200-day average ($27.22).
- 52-week range $15.93–$43.66; today's close sits at 35% of that range, 41.3% below the 52-week high.
- That makes 4 straight losses.
NGNE bull case vs bear case (from the data)
- No clear positive signal in the price trend, filings or insider data right now.
- Price is -25.9% vs its 50-day average — short-term trend is down.
- Price is -12.0% vs its 200-day average — below the long-term trend line.
- Annual revenue fell 100.0% in the latest fiscal year (SEC XBRL).
- Latest fiscal-year net income: loss of $90.35M.
- Insider selling outweighs buying: 25 sales vs 0 open-market buys among the 25 most recent reported insider trades (Form 4, last 12 months).
- Share count up 40.2% in a year (dilution).
- High volatility: average daily move of 4.0% over 20 sessions.
NGNE latest news & SEC filings
Every SEC filing by or about NGNE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 6, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mcminn Rachel converted options/RSUs into 756 shares at $25.32 (≈$19.14K) on Sep 22, 2026; now holds 1,345,063
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$34.49M (prior year -$22.02M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.53 (prior year -$1.05) (loss widened vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cvijic Christine Mikail sold 4,200 shares at $36.13 (≈$151.75K) on Jul 7, 2026
- Cvijic Christine Mikail sold 4,200 shares at $36.13 (≈$151.75K) on Jul 7, 2026
- Cvijic Christine Mikail sold 4,200 shares at $36.13 (≈$151.75K) on Jul 7, 2026
- Cvijic Christine Mikail sold 4,200 shares at $36.13 (≈$151.75K) on Jul 7, 2026
- Cvijic Christine Mikail sold 600 shares at $36.02 (≈$21.61K) on Jul 6, 2026
- Cvijic Christine Mikail sold 600 shares at $36.02 (≈$21.61K) on Jul 6, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cvijic Christine Mikail sold 2,531 shares at $34.58 (≈$87.52K) on Jul 2, 2026
- Cvijic Christine Mikail sold 1,530 shares at $35.23 (≈$53.90K) on Jul 2, 2026
- Cvijic Christine Mikail sold 2,531 shares at $34.58 (≈$87.52K) on Jul 2, 2026
- Cvijic Christine Mikail sold 1,530 shares at $35.23 (≈$53.90K) on Jul 2, 2026
- Cvijic Christine Mikail sold 2,531 shares at $34.58 (≈$87.52K) on Jul 2, 2026
- Cvijic Christine Mikail sold 1,530 shares at $35.23 (≈$53.90K) on Jul 2, 2026
- …plus 6 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 8.01 — Reported other events the company considers important.
Jul 2, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jun 30, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jun 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade NGNE
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 24, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.04% (largest 11.8%). That is a volatile stock.
- Liquidity: about 367.24K shares (≈$8.88M) trade per day on average.
- 52-week position: $24.17 vs a range of $15.93–$43.66 (30% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Christine Mikail Cvijic sold 4,200 shares on Jul 7, 2026.
- Latest filings: 10-Q Aug 11, 2026; 8-K Aug 11, 2026; 8-K Jul 2, 2026.
- Share count: 20.01M shares outstanding (Aug 7, 2026), +40.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
NGNE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 23.26 | 24.39 | 22.78 | 24.17 | 240.16K |
| Oct 16, 2026 | 24.00 | 24.27 | 23.00 | 23.25 | 571.50K |
| Oct 15, 2026 | 22.35 | 24.41 | 22.35 | 23.95 | 588.00K |
| Oct 14, 2026 | 21.05 | 22.50 | 21.05 | 22.18 | 522.40K |
| Oct 13, 2026 | 24.32 | 25.17 | 21.40 | 21.56 | 441.40K |
| Oct 12, 2026 | 26.13 | 27.15 | 24.19 | 24.44 | 387.00K |
| Oct 9, 2026 | 28.90 | 29.63 | 26.01 | 26.40 | 465.90K |
| Oct 8, 2026 | 28.00 | 28.97 | 26.24 | 26.50 | 509.40K |
| Oct 7, 2026 | 25.14 | 26.00 | 25.01 | 25.87 | 114.10K |
| Oct 6, 2026 | 26.63 | 26.74 | 25.04 | 25.45 | 121.60K |
| Oct 5, 2026 | 25.71 | 26.76 | 24.86 | 26.47 | 211.80K |
| Oct 2, 2026 | 26.95 | 26.95 | 24.86 | 25.65 | 401.60K |
| Oct 1, 2026 | 27.68 | 28.54 | 26.44 | 26.55 | 182.40K |
| Sep 30, 2026 | 28.52 | 28.61 | 27.40 | 27.82 | 160.10K |
| Sep 29, 2026 | 28.50 | 29.16 | 28.05 | 28.39 | 176.70K |
| Sep 28, 2026 | 28.20 | 28.82 | 27.64 | 28.48 | 176.40K |
| Sep 25, 2026 | 31.31 | 31.31 | 28.23 | 28.31 | 200.10K |
| Sep 24, 2026 | 30.85 | 31.78 | 30.43 | 31.25 | 374.90K |
| Sep 23, 2026 | 33.49 | 33.53 | 30.09 | 30.93 | 276.20K |
| Sep 22, 2026 | 32.94 | 34.45 | 32.79 | 33.60 | 1.22M |
About Neurogene
Neurogene (NGNE) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW YORK, NY. Fiscal year ends December 31. SEC CIK 1404644.
NGNE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Robert Baffi | Director | Feb 24, 2026 |
| Christine Mikail Cvijic | President and CFO | Jul 7, 2026 |
| Cory S. Freedland | Director | Feb 24, 2026 |
| Rachel Mcminn | Chief Executive Officer | Mar 30, 2026 |
| Sarah B. Noonberg | Director | Feb 24, 2026 |
| Rohan Palekar | Director | Feb 24, 2026 |
| Keith Woods | Director | Jun 16, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Stuart Cobb | Chief Scientific Officer | Mar 17, 2026 |
| Christine Mikail Cvijic | President and CFO | Jul 7, 2026 |
| Julie Jordan | Chief Medical Officer | Mar 30, 2026 |
| Rachel Mcminn | Chief Executive Officer | Mar 30, 2026 |
| Christina Shafer | Chief Commercial Officer | May 7, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 7, 2026 | Christine Mikail Cvijic | Sale | 4,200 | $36.13 |
| Jul 7, 2026 | Christine Mikail Cvijic | Sale | 4,200 | $36.13 |
| Jul 7, 2026 | Christine Mikail Cvijic | Sale | 4,200 | $36.13 |
| Jul 7, 2026 | Christine Mikail Cvijic | Sale | 4,200 | $36.13 |
| Jul 6, 2026 | Christine Mikail Cvijic | Sale | 600 | $36.02 |
| Jul 6, 2026 | Christine Mikail Cvijic | Sale | 600 | $36.02 |
| Jul 6, 2026 | Christine Mikail Cvijic | Sale | 600 | $36.02 |
| Jul 6, 2026 | Christine Mikail Cvijic | Sale | 600 | $36.02 |
| Jul 2, 2026 | Christine Mikail Cvijic | Sale | 2,531 | $34.58 |
| Jul 2, 2026 | Christine Mikail Cvijic | Sale | 1,530 | $35.23 |
| Jul 2, 2026 | Christine Mikail Cvijic | Sale | 2,531 | $34.58 |
| Jul 2, 2026 | Christine Mikail Cvijic | Sale | 1,530 | $35.23 |
| Jul 2, 2026 | Christine Mikail Cvijic | Sale | 2,531 | $34.58 |
| Jul 2, 2026 | Christine Mikail Cvijic | Sale | 1,530 | $35.23 |
| Jul 2, 2026 | Christine Mikail Cvijic | Sale | 2,531 | $34.58 |
NGNE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-90.35M | -4.24 | $-77.17M |
| Dec 31, 2024 | $925.00K | $-75.14M | -4.28 | $-70.60M |
| Dec 31, 2023 | $0 | $-36.32M | — | $-51.42M |
| Dec 31, 2022 | — | $-55.19M | -1.04 | $-52.82M |
| Dec 31, 2021 | — | $-60.69M | -1.10 | $-47.56M |
Latest balance sheet: total assets $244.36M, total liabilities $27.23M, cash $112.48M (as of Jun 30, 2026).
NGNE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $35.80 |
| May 12, 2026 | 8-K Item 2.02 (results) | $31.54 |
| Mar 24, 2026 | 8-K Item 2.02 (results) | $20.90 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $26.49 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $20.35 |
| May 9, 2025 | 8-K Item 2.02 (results) | $14.73 |
| Mar 24, 2025 | 8-K Item 2.02 (results) | $13.96 |
| Nov 18, 2024 | 8-K Item 2.02 (results) | $19.82 |
| Aug 9, 2024 | 8-K Item 2.02 (results) | — |
| May 10, 2024 | 8-K Item 2.02 (results) | — |
| Mar 18, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2022 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on NGNE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 19, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.